City of Hope Lymphoma SPORE

希望之城淋巴瘤孢子

• 批准号: 7493548
• 负责人: Stephen J Forman
• 金额: $ 216.33万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-02 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7493548
• 关键词: City; Hope; Lymphoma; SPORE

DESCRIPTION (provided by applicant): The overall goal of the City of Hope Lymphoma SPORE is to develop translational studies to improve the detection and therapy of Hodgkin's and non-Hodgkin's Lymphoma. This application consisting of four translational research projects and five cores will develop novel approaches that are derived from molecular and immunologic studies of T-cell and antibody-based therapies. An important theme of the translational studies in this grant is to develop lymphoma therapies that will reduce toxicities associated with current treatment regimens for Hodgkin's and non-Hodgkin's Lymphoma which can then be translated to the older patient population. One major goal is to develop anti-CD30 based radioimmunotherapy for both Hodgkin's and CD30+ non-Hodgkin's Lymphoma. A Second Project will study the effectiveness of cellular immunotherapy for follicular lymphoma utilizing engineered CD19-specific T-cells. Investigators in this project have developed a T-cell genetic modification platform for expressing chimeric immunoreceptors that redirect antigen specificity and effector function of T-cells towards cell surface epitopes on lymphomas. Because epidemiologic studies indicate that stem cell damage from pretransplant therapeutic exposures may play a role in the development of myelodysplasia, a Third Project will longitudinally study a population of patients with Hodgkin's and non-Hodgkin's Lymphoma to investigate the cellular and molecular factors that are predictive for development of myelodysplasia, and to determine the molecular sequence of events that lead to myelodysplasia. In a Fourth Project, investigators will develop molecularly engineered constructs for anti-CD20 directed therapeutics to improve imaging, radioimmunotherapy, and novel immunocytokines for the treatment of patients with CD20+ lymphoma. An important component of this project will be to delineate the immunologic effector mechanisms operative in immunocytokine-mediate anti-lymphoma in vivo activity. The projects in this Lymphoma SPORE will be supported by five cores including: Administration, Biostatistics and Data Management, Tissue Bank for molecular and cellular studies, Biological Material Production, and Animal Models and Assays. This Lymphoma SPORE will also support a Developmental Research Program and a Career Development Program to foster the advancement of pilot translational research projects and young investigators focused on lymphoma.

描述（由申请人提供）：希望之城淋巴瘤 SPORE 的总体目标是开展转化研究，以改进霍奇金淋巴瘤和非霍奇金淋巴瘤的检测和治疗。 该应用程序由四个转化研究项目和五个核心组成，将开发源自 T 细胞和抗体疗法的分子和免疫学研究的新方法。 这笔赠款转化研究的一个重要主题是开发淋巴瘤疗法，以减少与当前霍奇金和非霍奇金淋巴瘤治疗方案相关的毒性，然后将其推广到老年患者群体。 一个主要目标是开发针对霍奇金淋巴瘤和 CD30+ 非霍奇金淋巴瘤的基于抗 CD30 的放射免疫疗法。第二个项目将研究利用工程化 CD19 特异性 T 细胞进行细胞免疫疗法治疗滤泡性淋巴瘤的有效性。 该项目的研究人员开发了一种 T 细胞基因修饰平台，用于表达嵌合免疫受体，将 T 细胞的抗原特异性和效应器功能重定向到淋巴瘤的细胞表面表位。 由于流行病学研究表明，移植前治疗暴露造成的干细胞损伤可能在骨髓增生异常的发展中发挥作用，因此第三个项目将纵向研究霍奇金淋巴瘤和非霍奇金淋巴瘤患者群体，以研究预测骨髓增生异常的细胞和分子因素。骨髓增生异常的发展，并确定导致骨髓增生异常事件的分子序列。 在第四个项目中，研究人员将开发用于抗 CD20 定向治疗的分子工程结构，以改善成像、放射免疫疗法和用于治疗 CD20+ 淋巴瘤患者的新型免疫细胞因子。 该项目的一个重要组成部分将是描述在免疫细胞因子介导的抗淋巴瘤体内活性中起作用的免疫效应机制。淋巴瘤 SPORE 中的项目将得到五个核心的支持，包括：管理、生物统计和数据管理、分子和细胞研究组织库、生物材料生产以及动物模型和测定。该淋巴瘤孢子还将支持发展研究计划和职业发展计划，以促进试点转化研究项目和专注于淋巴瘤的年轻研究人员的进步。